ResultsIQ

ResultsIQ › Latest results › Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited investor presentation summary

NSE: ONESOURCE · BSE: 544292

Investor presentation of 3 Sep 2026, summarised by AI from the filing.

OneSource Specialty Pharma filed its investor presentation with the exchanges after an analyst and institutional investor meeting at its Unit II facility on September 03, 2026.

Key takeaways

  1. Investor meeting An analyst and institutional group investor meeting was held on September 03, 2026 at the manufacturing facility (Unit II) in Doddaballapura, Bengaluru.
  2. Presentation The company uploaded its latest investor presentation to its website and asked the exchanges to take it on record.
  3. Filing The intimation was filed with BSE and NSE on September 03, 2026 under scrip code 544292 and symbol ONESOURCE.
  4. Prior intimation The company referred to its intimation dated August 31, 2026 about the investor meeting.
  5. Signatory The letter was signed by Trisha A, Company Secretary and Compliance Officer, membership number A47635.

Original filing on BSE

Onesource Specialty Pharma Limited Q1 FY27 results

As filed: Revenue ₹449 cr (+37% year on year), EBITDA ₹123 cr (+39% year on year), PAT ₹25.0 cr, EBITDA margin 27.5% (+25 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹428 cr (+1% year on year), EBITDA ₹91.9 cr (−49% year on year), PAT ₹4.6 cr (−100% year on year), EBITDA margin 21.5% (−1,000 bps). Score 9 of 100, Below trend. EBITDA margin fell 1000 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −9.9% in 30 days (Nifty 500: +1.0%).
  • Q3 FY26: Revenue ₹290 cr (−26% year on year), EBITDA ₹17.3 cr (−88% year on year), PAT −₹88.7 cr, EBITDA margin 6.0% (−1,000 bps). Score 0 of 100, Below trend. EBITDA margin fell 1000 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 23% from last quarter. Share price after the results: −25.0% in 30 days (Nifty 500: +0.7%).
  • Q2 FY26: Revenue ₹376 cr (+300% year on year), EBITDA ₹107 cr, PAT ₹10.0 cr, EBITDA margin 28.5% (+1,000 bps). Score 88 of 100, Above trend. EBITDA margin rose 1000 bps year on year. Other income 50% of PBT. Tax rate -83%. Not enough history for a trend yet: scored on growth alone. Share price after the results: −5.6% in 30 days (Nifty 500: −0.6%).
  • Q1 FY26: Revenue ₹321 cr, EBITDA ₹80.0 cr, PAT ₹25.0 cr, EBITDA margin 24.9%. Not scored. No result for the same quarter last year. Share price after the results: −4.1% in 29 days (Nifty 500: −2.5%).
  • Q4 FY25: Revenue ₹477 cr, EBITDA ₹237 cr, PAT ₹174 cr, EBITDA margin 49.7%. Not scored. No result for the same quarter last year. Share price after the results: +17.5% in 30 days (Nifty 500: +2.8%).
  • Q3 FY25: Revenue ₹337 cr, EBITDA ₹101 cr, PAT −₹73.0 cr, EBITDA margin 30.0%. Not scored. No result for the same quarter last year.
  • Q2 FY25: Revenue ₹68.0 cr, EBITDA ₹0.0 cr, PAT −₹40.0 cr, EBITDA margin 0.0%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Onesource Specialty Pharma Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.